6-quinolinecarboxylic acid chloride hydrochloride | 158000-98-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-quinolinecarboxylic acid chloride hydrochloride
• 英文别名: 6-quinolinecarbonyl chloride hydrochloride；Quinoline-6-carbonyl chloride hydrochloride；quinoline-6-carbonyl chloride;hydrochloride
• CAS: 158000-98-7
• 化学式: C₁₀H₆ClNO*ClH
• mdl: MFCD11501925
• 分子量: 228.078
• InChiKey: QXRUURIWNYPMGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.32
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  金刚烷胺 、 6-quinolinecarboxylic acid chloride hydrochloride 在 吡啶 作用下， 以 水 为溶剂， 以330 mg (11%)的产率得到N-(1-Adamantyl)-6-quinolinecarboxamide
  参考文献：
  名称：

  Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases

  摘要：

  本发明提供了在代谢型谷氨酸受体上具有活性的化合物和含有这些化合物的药物组合物，这些化合物对治疗神经系统疾病和障碍是有用的。同时还公开了制备这些化合物的方法。

  公开号：

  US06429207B1
• 作为产物：
  描述：

  喹啉-6-羧酸 、 氯化亚砜 在 氯化亚砜 作用下， 反应 0.5h， 以to provide 6-quinolinecarbonyl chloride hydrochloride的产率得到6-quinolinecarboxylic acid chloride hydrochloride
  参考文献：
  名称：

  Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases

  摘要：

  本发明提供了在代谢型谷氨酸受体上活性的化合物和含有这些化合物的药物组合物，这些化合物可用于治疗神经系统疾病和障碍。本发明还揭示了制备这些化合物的方法。

  公开号：

  US07053104B2

文献信息

• Hepatitis C Virus Inhibitors
  申请人：Scola Paul Michael

  公开号：US20080014173A1

  公开（公告）日：2008-01-17

  Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  揭示了具有一般结构式的丙型肝炎病毒抑制剂。还揭示了包含这些化合物的组合物和使用这些化合物来抑制HCV的方法。
• Adducts of phenanthrene 9,10-imine and of benz[<i>a</i>]anthracene 5,6-imine to some nitrogen heterocycles
  作者：Yosef Shalom、Jochanan Blum、Ronald G. Harvey

  DOI：10.1002/jhet.5570330327

  日期：1996.5

  N-4-Pyridinyl-, N-2-quinolinyl-, and 2-pyrazinylphenanthrene 9,10-imines 4–6, as well as N-4-pyridinyl- and N-2-pyrazinylbenz[a]anthracene 5,6-imines 12 and 13 were prepared by sodium hydride-mediated interaction of the parent arene imines, 1 and 10, and the respective chloropyridine, chloroquinoline or chloropyrazine. N-Nicotynoyl-, N-2-pyridinoyl- and N-6-quinolinoylphenanthrene 9,10-imines 7–9 were

  Ñ -4-吡啶基，Ñ -2- quinolinyl-和2- pyrazinylphenanthrene -9,10-亚胺4-6，以及ñ -4-吡啶基和Ñ -2- pyrazinylbenz [一个]蒽5,6-通过氢化钠介导的母体芳烃亚胺1和10与各自的氯吡啶，氯喹啉或氯吡嗪的相互作用制备亚胺12和13。Ñ -Nicotynoyl-，Ñ -2- pyridinoyl-和Ñ -6- quinolinoylphenanthrene -9,10-亚胺7-9通过的相互作用获得Ñ-三甲基甲硅烷基菲9,10-亚胺（2）和合适的吡啶或喹啉羰基氯化物。的反应Ñ -methylsulfonylphenanthrene -9,10-亚胺与胸腺嘧啶，胞嘧啶，5-氟胞嘧啶，嘌呤，6-氯嘌呤和腺嘌呤，得到，在任一碳酸钾或1,5-二氮杂双环[3.4.0]壬-5-的存在烯，分别为加合物16-22。加合物的结构通过多核核磁
• Condensed Imidazole Compound And Use Thereof
  申请人：Uchikawa Osamu

  公开号：US20080167314A1

  公开（公告）日：2008-07-10

  The present invention relates to a compound represented by the formula [I] wherein X 1 , X 2 and X 3 are each an optionally substituted CH or a nitrogen atom, and any one of X 1 , X 2 and X 3 is a nitrogen atom, X 4 is an optionally substituted CH, R 1 is an optionally substituted phenyl group or an optionally substituted heterocyclic group, and R 2 is an optionally substituted pyridin-4-yl group, an optionally substituted pyridine-N-oxide-4-yl group or an optionally substituted pyrimidin-4-yl group, or a salt thereof. The compound has superior p38 MAP kinase inhibitory activity and MMP-13 production inhibitory activity, and is useful as an agent for the prophylaxis or treatment and the like of an inflammatory disease, an autoimmune disease, a debilitating disease, an osteoarticular degenerative disease, a neurodegenerative disease, a vascular disease, a neoplastic disease or an infectious disease.

  本发明涉及一种化合物，其表示为式[I]，其中X1、X2和X3分别是可选取代的CH或氮原子，且X1、X2和X3中的任意一个是氮原子，X4是可选取代的CH，R1是可选取代的苯基或可选取代的杂环基，R2是可选取代的吡啶-4-基、可选取代的吡啶-N-氧化物-4-基或可选取代的嘧啶-4-基，或其盐。该化合物具有优异的p38 MAP激酶抑制活性和MMP-13产生抑制活性，可用作预防或治疗炎症性疾病、自身免疫疾病、虚弱性疾病、骨关节退行性疾病、神经退行性疾病、血管疾病、肿瘤性疾病或感染性疾病的药物等。
• CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1832588A1

  公开（公告）日：2007-09-12

  The present invention relates to a compound represented by the formula [I] wherein X1, X2 and X3 are each an optionally substituted CH or a nitrogen atom, and any one of X1, X2 and X3 is a nitrogen atom, X4 is an optionally substituted CH, R1 is an optionally substituted phenyl group or an optionally substituted heterocyclic group, and R2 is an optionally substituted pyridin-4-yl group, an optionally substituted pyridine-N-oxide-4-yl group or an optionally substituted pyrimidin-4-yl group, or a salt thereof. The compound has superior p38 MAP kinase inhibitory activity and MMP-13 production inhibitory activity, and is useful as an agent for the prophylaxis or treatment and the like of an inflammatory disease, an autoimmune disease, a debilitating disease, an osteoarticular degenerative disease, a neurodegenerative disease, a vascular disease, a neoplastic disease or an infectious disease.

  本发明涉及一种由式 [I] 表示的化合物 其中X1、X2和X3各自为任选取代的CH或氮原子，且X1、X2和X3中的任一个为氮原子，X4为任选取代的CH，R1为任选取代的苯基或任选取代的杂环基团，R2为任选取代的吡啶-4-基团、任选取代的吡啶-N-氧化-4-基团或任选取代的嘧啶-4-基团，或其盐。该化合物具有优异的 p38 MAP 激酶抑制活性和 MMP-13 生成抑制活性，可用于预防或治疗炎症性疾病、自身免疫性疾病、衰弱性疾病、骨关节退行性疾病、神经退行性疾病、血管性疾病、肿瘤性疾病或传染性疾病等。
• METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES
  申请人：NPS PHARMACEUTICALS, INC.

  公开号：EP1037878A2

  公开（公告）日：2000-09-27